Episode Details
Back to EpisodesDurvalumab’s Benefit in SCLC ”Beyond What We Might Have Expected”
Published 1 year, 9 months ago
Description
From ASCO 2024, Dr. Robert Figlin talks with Dr. Lauren Averett Byers from MD Anderson Cancer Center.
Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"